2026-2034年全球思觉失调症治疗药物市场规模、份额、趋势和成长分析报告

预计到 2034 年，思觉失调症治疗市场规模将从 2025 年的 96.9 亿美元增长至 148.7 亿美元，并预计从 2026 年到 2034 年将以 4.87% 的复合年增长率增长。

世界の精神疾患の有病率増加とメンタルヘルスへの意识提升により、思觉失调症治疗薬市场は着実に成长しております。都市区のストレス、薬物乱用、遗伝的素因が主な要因です。政府やヘルスケア机関は早期诊断と治疗アクセスの重要性を强调しており、ヘルスケア保険适用范囲の拡大やメンタルヘルス支援プログラムの拡充が处方率向上を促进しております。製薬企业は患者の服薬遵守率と治疗効果の向上を目指し、长时间作用型注射用抗精神病薬の开発に注力しております。

非典型抗精神病药物安全性的提高也推动了市场成长。旨在减少体重增加和代谢併发症等副作用的新型药物製剂备受关注。神经科学研究投入的增加正在加速药物研发管线的发展。数位健康平台和远距精神科服务正在扩大患者的就医途径。此外，研究机构和製药公司之间的合作正在增强创新能力并推进临床试验。

未来，个人化医疗和基于生物标记的治疗方法有望变革治疗策略。亚太和拉丁美洲等新兴市场由于精神卫生基础设施的改善，预计将迎来显着成长。创新药物候选产品的持续核准将加剧市场竞争。持续进行的提高公众意识的宣传活动和消除精神健康污名的倡议将为长期增长提供支持。总体而言，创新和可及性仍将是市场扩张的关键决定因素。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球思觉失调症治疗市场：依治疗领域划分

• 市场分析、洞察与预测
• 第二代
• 第三代
• 其他的

第五章 全球思觉失调症治疗市场：依治疗方法划分

• 市场分析、洞察与预测
• 口服
• 注射药物

第六章 全球思觉失调症治疗市场：依分销管道划分

• 市场分析、洞察と予测
• 医院药房
• 零售药房
• 网路药房
• 其他的

第七章 全球思觉失调症治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • H. Lundbeck A/S
  • Otsuka Pharmaceutical Co. Ltd
  • Janssen Pharmaceuticals Inc
  • Eli Lilly And Company
  • AstraZeneca
  • ALLERGAN
  • Vanda Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co. Ltd
  • Alkermes Plc
  • Bristol-Myers Squibb Company

The Schizophrenia Drugs Market size is expected to reach USD 14.87 Billion in 2034 from USD 9.69 Billion (2025) growing at a CAGR of 4.87% during 2026-2034.

The Global Schizophrenia Drugs Market is growing steadily due to increasing mental health awareness and rising prevalence of psychiatric disorders globally. Urban stress, substance abuse, and genetic predisposition are key contributing factors. Governments and healthcare organizations are emphasizing early diagnosis and treatment accessibility. The expansion of healthcare coverage and mental health funding programs is encouraging higher prescription rates. Pharmaceutical companies are focusing on developing long-acting injectable antipsychotics to improve patient adherence and therapeutic effectiveness.

Market growth is also driven by advancements in atypical antipsychotic medications with improved safety profiles. Novel drug formulations targeting reduced side effects such as weight gain and metabolic complications are gaining traction. Increasing investments in neuroscience research are accelerating pipeline developments. Digital health platforms and telepsychiatry services are expanding patient outreach. Additionally, collaborations between research institutions and pharmaceutical firms are strengthening innovation capabilities and clinical trial progress.

In the future, personalized medicine approaches and biomarker-based therapies are expected to transform treatment strategies. Emerging markets in Asia-Pacific and Latin America are anticipated to witness significant growth due to improving psychiatric care infrastructure. Ongoing regulatory approvals for innovative drug candidates will enhance competition. Long-term growth will be supported by continuous awareness campaigns and mental health de-stigmatization initiatives. Overall, innovation and accessibility will remain key determinants of market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Class

• Second Generation
• Third Generation
• Others

By Treatment

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• H Lundbeck AS, Otsuka Pharmaceutical Co Ltd, Janssen Pharmaceuticals Inc, Eli Lilly and Company, AstraZeneca, ALLERGAN, Vanda Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Alkermes plc, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY THERAPEUTIC CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Class
• 4.2. Second Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Third Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutic Class
  • 7.2.2 By Treatment
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutic Class
  • 7.3.2 By Treatment
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutic Class
  • 7.4.2 By Treatment
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutic Class
  • 7.5.2 By Treatment
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutic Class
  • 7.6.2 By Treatment
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SCHIZOPHRENIA DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 H. Lundbeck A/S
  • 9.2.2 Otsuka Pharmaceutical Co. Ltd
  • 9.2.3 Janssen Pharmaceuticals Inc
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 AstraZeneca
  • 9.2.6 ALLERGAN
  • 9.2.7 Vanda Pharmaceuticals Inc
  • 9.2.8 Sumitomo Dainippon Pharma Co. Ltd
  • 9.2.9 Alkermes Plc
  • 9.2.10 Bristol-Myers Squibb Company